Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 1

Conditions

Carcinoma, Renal Cell 37Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasm Metastasis 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Squamous Cell Carcinoma of Head and Neck 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Ovarian Neoplasms 2Melanoma 2Clear-cell metastatic renal cell carcinoma 2Brain Neoplasms 2von Hippel-Lindau Disease 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1

Interventions

pembrolizumab 7padeliporfin 5Nivolumab 4Everolimus 4Sunitinib 3Sorafenib 3Mitomycin 3fludarabine 2epothilone B 2durvalumab 2cabozantinib 2Ipilimumab 2Cyclophosphamide 2Cisplatin 21-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2volociximab 1vinflunine 1sipuleucel-T 1sargramostim 1pemigatinib 1palladium-bacteriopheophorbide 1palbociclib 1obinutuzumab 1luprolide acetate gel depot 1lenvatinib 1ixabepilone 1fludarabine phosphate 1enzalutamide 1belzutifan 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × lenvatinib × Genitourinary × Clear all
NCT02454478 2019-03-19

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

Eisai Inc.

Phase 1 Completed
7 enrolled 17 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡